"Recurrent glioblastoma" trang 1 - tải miễn phí từ tailieunhanh
Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: A retrospective study

Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: A retrospective study
8    89    0
VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma

VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma
7    40    1
Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1)

Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1)
10    71    1
Use of Bevacizumab in recurrent glioblastoma: A scoping review and evidence map

Use of Bevacizumab in recurrent glioblastoma: A scoping review and evidence map
23    8    1
Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma – the GlioCave study (NOA 17 – ARO 2016/3 – DKTK ROG trial)

Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma – the GlioCave study (NOA 17 – ARO 2016/3 – DKTK ROG trial)
5    56    1
Limited recurrence distance of glioblastoma under modern radiotherapy era

Limited recurrence distance of glioblastoma under modern radiotherapy era
8    21    1
Báo cáo khoa học:

Báo cáo khoa học: " Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme"
7    37    0
Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism

Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism
10    36    0
Crosslink between Temozolomide and PDL1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PDL1 immune-checkpoint inhibition in glioblastoma multiforme
7    94    1
Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients
10    54    1
Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma

Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma
7    48    1
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status

Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
13    46    1